Linkage Tool for One Health and Antimicrobial Resistance (AMR) research
To achieve the goals and objectives of the AMR Research Initiative, strong connections must be made across disciplines and sectors to support a multidisciplinary, One Health approach that considers the interplay of human, animal, agriculture and agri-food, and environmental health. One of the ways the CIHR is supporting the development of such connections is through this linkage tool.
This linkage tool is designed to facilitate partnerships between researchers as well as government officials, NGOs, community-based organizations or others to support the co-creation and mobilization of research evidence into programs, policies and practice to advance AMR research and improve the health of people in Canada. This tool will help connect potential partners that are working in an area of mutual interest. For example, health researchers could indicate to environmental researchers or policymakers their interest in conducting research on specific matters involving existing data, whereas communities could indicate to researchers their interest in becoming a site for implementation projects.
Please refer to the funding opportunity on ResearchNet to confirm eligibility requirements.
Notice
IMPORTANT: To be included in the linkage tool, please complete this short form. Your information will be added to the table below during the next update.
The table below shows information submitted by researchers, governmental officials, and representatives from NGOs, community-based organizations or others that are interested in sharing information and/or forging collaborations in relation to One Health and AMR research.
Information is posted in the language in which it was submitted. It is provided on a voluntary basis and in no way confers any advantages in the evaluation and/or funding of applications.
The table will usually be updated weekly, until April 28, 2026 and regularly thereafter.
|
Contact information Name Name of community, institution, organization or other Province/Territory Phone Number (optional) Website Address (optional) |
Role(s) | One Health Sector(s) | Domain(s) of expertise | Additional Information |
|---|---|---|---|---|
|
Jennifer Geddes-McAlister |
Mid-career researcher | Human health, Animal health | Microbiology, Immunology, Bioinformatics and/or Computational Biology, Treatments, Diagnostics, Vaccines Additional expertise: Antifungal resistance, fungal pathogenesis, mass spectrometry-based proteomics, systems biology |
Research partners, clinical partners, outreach and knowledge translation. Moving discoveries in the lab to translational applications of value within the market, community, and clinical practice. |
|
Joel Finbloom |
Early career researcher | Human health | Microbiology, Treatments, Infection prevention and control Additional expertise: Expertise in drug delivery and nanomedicine, with a focus on antimicrobial delivery to treat bacterial biofilm infections. |
Interested in forming collaborations or partnerships with microbiologists, physician scientists, and medicinal chemists. My lab has expertise in advancing the packaging and delivery of antimicrobials, and we are interested in improving efficacy of existing and emerging antimicrobial therapeutics, co-delivery of synergistic antimicrobials, and partnering with researchers focused on a specific infection model or disease. |
|
Neeraj Dhar |
Mid-career researcher | Human health, Animal health | Microbiology, Treatments, Vaccines Additional context: Vaccine and Infectious Disease Organization (VIDO) is a research center and part of the University of Saskatchewan (USask) and is located on the campus of USask, Saskatoon, Saskatchewan Canada. VIDO’s vision is Healthy People, Healthy Animals with the mission to protect the world from infectious diseases. VIDO is one of the largest, most advanced, containment facilities in the world, comprising ~100,000 ft2 of BSL2 space, 20 BSL2-Ag animal rooms, ~180,000 ft2 of BSL3/BSL3-Ag space and BSL4 space in development. In addition, VIDO has a 160-acre research station for large animals and has recently added a 7,500 ft2 BSL3 capable cGMP biologics manufacturing facility referred to as the ‘Vaccine Development Centre’ (VDC). Dr. Neeraj Dhar leads the Laboratory of Infection Biology and Imaging research group at VIDO. Research within the laboratory focuses on three main themes 1) Bacterial persistence against antibiotics, with the aim of discovering anti-persister compounds to accelerate antimicrobial chemotherapy, 2) Exploring phenotypic heterogeneity in bacterial infections especially in the context of infection and host-pathogen interactions and 3) Developing three-dimensional (3D) microtissue models for studying respiratory infections. The proposed research builds on the tools and reagents developed by Dr. Dhar over the past 10-15 years, utilizing innovative microfluidic platforms and advanced timelapse microscopy systems for single-cell microbiology. In addition to standard laboratory equipment, the lab is equipped with an automated live cell imaging system that can be used to acquire long-term high-resolution live-cell images of bacteria, cell cultures as well as tissue samples. The system is fully equipped with environmental control over temperature, CO2 and oxygen. So essentially we are equipped to test experimental compounds against wide variety of bacterial pathogens in vitro at the single-cell level to in vivo in different animal models in different levels of containment. |
I'm interested in establishing cross-sectoral linkages and look to connect with partners in academia, clinical laboratories, public health institutions, agri-food industry stakeholders who bring complementary expertise in chemistry, compound screening, epidemiology, and translational research. Our community faces challenges due to limited integration of human, animal and environmental AMR data and significant gaps in surveillance, advanced imaging and data analysis. Desired outcomes of these linkages would be to foster multi-disciplinary collaborations that facilitate a holistic approach to AMR |
|
Fiona F Hunter |
Senior researcher | Human health, Animal health, Environmental health | Surveillance, Diagnostics, Microbiology Additional context: I am the Director of Brock University's Containment Level 3 (CL3) lab that also includes a CL3 insectary. We have done work on arboviruses and the mosquitoes that transmit them, with an emphasis on West Nile virus, Zika virus and Mayaro virus. However, we are able to work on other BSL-3 agents (after PHAC approval of protocols) that may be of interest. We can offer our CL3 Services to a One-Health project under this grant opportunity. |
We are interested in supporting other research groups. |
| Pingzhao Hu phu49@uwo.ca Department of Biochemistry, Department of Computer Science, Western University Ontario 519-661-2111 (89276) The Hu Lab |
Mid-career researcher | Human health |
Bioinformatics and/or Computational Biology, Modeling Additional context: Dr. Hu is a Canada Research Chair (Tier 2) in Computational Approaches to Health Research and a recognized expert in applying artificial intelligence to antibiotic discovery and de novo drug design. He leads an interdisciplinary research team focused on developing advanced AI algorithms and systems to accelerate the discovery of novel therapeutics. His research program is supported by CIHR Project Grants and the Canada–France AI Initiative. Dr. Hu’s work has led to significant contributions to the field, with findings published in leading scientific journals and top-tier AI conferences. More information about his research and publications is available at https://phulab.org/ |
We welcome opportunities to collaborate with teams seeking our expertise. |
| Derek Dee derek.dee@ubc.ca University of British Columbia British Columbia Derek Dee Lab |
Mid-career researcher | Agriculture and agri-food, Animal health, Human health |
Food Science and/or Safety, Microbiology, Bioinformatics and/or Computational Biology Additional context: Bacterial amyloid (curli) is an established target of anti-biofilm drug treatments, but rigorous antimicrobial treatments are hindered by a lack of detailed understanding of the fibril structure and dynamic assembly process. We use biophysical tools to resolve the structural mechanism of curli amyloid assembly, from single protein molecules and small oligomers (optical tweezers) to mature amyloid fibres (cryoEM) to define drug targets and examine the mechanism of existing inhibitors. |
Looking to contribute our expertise in studying molecular mechanisms of curli (biofilm) assembly as part of a larger team focused in any/all areas of AMR related to biofilm (health, food, animal, environment). |
| John Gill John.gill@ahs.ca University of Calgary and S Alberta HIV clinic Alberta 403-955-6399 |
Senior researcher, Clinician | Human health |
Microbiology, Surveillance, Bioinformatics and/or Computational Biology, Treatments, Economics Additional context: Clinician, researcher with interest in virology, Program administrator |
The s Alberta HIV clinic, which provides care to all HIV person in S Alberta, has bio banked intake samples (ie plasma virus) on 90% of patients entering our care since 1989 (n>6000 unique persons). We also have many samples at time of antiretroviral failure. In addition, we have all patients' viral sequences undertaken for resistance testing at time of treatment failure. When combined with our detailed host's extensive clinical, laboratory, antiretroviral treatment and social details we are exploring viral evolution, emergent antiretroviral resistance (and its costs) in a large geographically defined high characterized, genetically diverse real-world population. Collaborations comparing our population to others with regard to treatment care strategies, ART use, transmission risk co factors would be helpful as would more intense virology studies looking at extensive viral and host factors driving emergent resistance. |
- Date modified: